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SUMMARY
During progression of atherosclerosis, myeloid cells destabilize lipid-rich plaque in the arterial
wall and cause its rupture, thus triggering myocardial infarction and stroke. Survivors of acute
coronary syndromes have a high risk of recurrent events for unknown reasons. Here we show that
the systemic response to ischemic injury aggravates chronic atherosclerosis. After myocardial
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tinfarction or stroke, apoE−/− mice developed larger atherosclerotic lesions with a more advanced
morphology. This disease acceleration persisted over many weeks and was associated with
markedly increased monocyte recruitment. When seeking the source of surplus monocytes in
plaque, we found that myocardial infarction liberated hematopoietic stem and progenitor cells
from bone marrow niches via sympathetic nervous system signaling. The progenitors then seeded
the spleen yielding a sustained boost in monocyte production. These observations provide new
mechanistic insight into atherogenesis and provide a novel therapeutic opportunity to mitigate
disease progression.
INTRODUCTION
Today, survival following a first myocardial infarct (MI) approaches 90%. However, re-
infarction occurs commonly and carries a high mortality. In a representative trial, new
myocardial ischemia occurred in 54% of patients within the first year after MI1. The largest
population study to date showed a 17.4% 1-year risk of re-infarction2. Conventional wisdom
infers that these very high rates of secondary events reflect later stages of linear disease
progression. This study tested the alternative hypothesis that a first infarct — triggering a
burst of acute systemic inflammation aimed at repair of the injured heart —could accelerate
atherosclerosis.
Monocytes infiltrate lesions and, together with their lineage descendant macrophages,
instigate inflammation and deliver proteolytic enzymes that digest extracellular matrix and
render atherosclerotic plaques unstable3–7. Elevated levels of circulating monocytes provide
an expanded pool of inflammatory cells available for recruitment to growing arterial lesions,
potentially promoting plaque rupture. Leukocytosis post MI predicts an increased risk of re-
infarction and death8,9. During acute MI, blood monocyte levels spike, and these cells
accumulate in the evolving myocardial wound10,11. Thus, the organism experiences an acute
inflammatory event (e.g. MI) superimposed on a pre-existing chronic inflammatory disease
(atherosclerosis), both of which involve the same myeloid cell type. Given the frequency of
re-infarction, we investigated whether acute myocardial injury accelerates pre-existing
chronic atherosclerosis.
We found that in apoE−/− mice with atherosclerosis, MI increased plaque size and induced a
'vulnerable' lesion morphology with higher inflammatory cell content and protease activity,
fueled by persistently increased myeloid cell flux to atherosclerotic sites. Earlier clinical
studies described an increase of hematopoietic stem and progenitor cells (HSPCs) in the
circulation of patients shortly after MI12. We thus hypothesized that release of these
progenitors may increase the availability of monocytes. We found that in response to
heightened sympathetic nervous system (SNS) activity — provoked by pain, anxiety, and
heart failure in patients with MI HSPCs departed bone marrow niches and produced
prolonged amplified extramedullary monocytopoiesis in mice after coronary ligation.
MI accelerates atherosclerosis
Proteases, including metalloproteinases and cysteinyl cathepsins, can catabolize the
extracellular matrix of the plaque’s fibrous cap and render it prone to rupture13,14.
Therefore, protease activity may serve as a marker in mice of processes associated with
lesion vulnerability in humans15. To test the hypothesis that MI changes the course of
atherosclerotic disease, we serially imaged protease activity in aortic plaques of apoE−/−
mice, before and 3 weeks after coronary ligation, using fluorescence molecular tomography
fused to X-ray computed tomography (FMT/CT)16. Imaging showed a sharp increase of
plaque protease activity within 3 weeks after MI (Fig. 1a,b). In parallel, expression of the
inflammatory cytokine IL-6, MMP-9, myeloperoxidase, and Ly-6C increased in
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tatherosclerotic plaques (Supplementary Fig. 1). The number of monocytes/macrophages per
aorta expanded, particularly the inflammatory Ly-6Chigh monocyte subset (Fig. 1c). Plaque
monocyte content also increased in apoE−/− mice without MI, reflecting the natural course
of disease in these animals17,18. Yet innate immune cell accumulation accelerated
distinctively after MI, as indicated by the significantly greater slope obtained when fitting
the number of Ly-6Chigh monocytes in the aorta over time (Supplementary Fig. 2).
Neutrophil presence in atheromata also increased (Supplementary Fig. 3) while mast cells
did not (Supplementary Fig. 4). Histologic analysis affirmed increased accumulation of
CD11b+ myeloid cells and larger lesion size after MI (Fig. 1d). The thickness of the fibrous
cap decreased, covering larger necrotic cores (Supplementary Fig. 5). Ly-6Chigh monocytes
isolated from atherosclerotic lesions exhibited higher levels of mRNAs encoding
inflammatory genes. IL-1β and cathepsin B were expressed at higher levels 3 weeks after
MI, whereas arginase-1 and TGFβ, markers associated with alternatively activated
macrophages, were expressed at lower levels (Supplementary Fig. 6). Monocyte numbers in
the blood and spleen increased consistently for up to 3 months after coronary ligation
(Supplementary Fig. 7) but were unaltered in the bone marrow (Supplementary Fig. 8).
Extramedullary monocytopoiesis post MI
Because the spleen has the ability to host extramedullary hematopoiesis19–21, we measured
splenic monocyte progenitor content following MI. Hematopoietic progenitor cell numbers
in the spleen increased post-MI (Fig. 2, Supplementary Fig. 9) but not in the bone marrow
(Supplementary Fig. 10). Proliferation of progenitors doubled in the spleen (Supplementary
Fig. 11). In patients that died after an acute MI, we found increased numbers of c-kit+ cells
in the spleen, some of which colocalized with the proliferation marker Ki-67
(Supplementary Fig. 12).
When we splenectomized mice at the time of MI, atherosclerosis did not
accelerate(Supplementary Fig. 13). The number of progenitor cells in liver tissue after MI
was much lower than in the spleen, however; splenectomy increased progenitor cell
presence in the liver 4 days after MI (Supplementary Fig. 14). We concluded that the infarct-
induced monocytosis resulted primarily from augmented production in the spleen, but other
extramedullary sites may contribute22. This observation raised the question whether
monocytes of splenic and bone marrow origin differ qualitatively. Surprisingly, Ly-6Chigh
monocytes isolated from the spleen or bone marrow on day 4 after MI had significantly
different mRNA levels in 11 of the 32 genes assessed (Supplementary Fig. 15). For instance,
IL-1β and cathepsin B mRNA levels were 60- and 6-fold higher in inflammatory monocytes
isolated from the spleen, matching the increased expression of these genes in Ly-6Chigh
monocytes isolated from atherosclerotic plaque after MI (Supplementary Fig. 6). Therefore,
post-MI extramedullary myelopoiesis may not only increase the availability of inflammatory
cells but also change their functional program. To test whether another form of acute tissue
injury prevalent in atherosclerotic patients would accelerate splenic myelopoiesis, we
analyzed apoE−/−mice 6 weeks after ischemic stroke. The number of myeloid cells and
Ly-6Chigh monocytes in atherosclerotic plaque increased after stroke, in parallel with
expanded splenic monocytopoiesis (Supplementary Fig. 16).
Bone marrow HSPC release post MI
Since granulocyte macrophage progenitors (GMP) and macrophage dendritic cell
progenitors (MDP) have a limited self-renewal capacity23,24, we hypothesized that upstream
progenitors released from their bone marrow niches sustain the splenic proliferative activity
after MI. Indeed, blood levels of HSPCs increased 2, 7 and 24-fold at 6, 48 and 96 hours
after MI, respectively (Fig. 3a, ). The number of splenic FLK2− HSPCs increased
dramatically after MI (Supplementary Fig. 17). This mobilization of upstream HSPCs with
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thigh capacity for self-renewal likely explains the long-term boost in splenic monocyte
production in apoE−/− mice after MI.
Anxiety, pain and impaired left ventricular function during MI can all activate the SNS.
Accordingly, levels of tyrosine hydroxylase, the rate-limiting enzyme for production of
noradrenaline in sympathetic fibers25, increased in the bone marrow of mice after MI and
hence indicated a higher sympathetic tone (Fig. 3b). SNS activity may liberate
hematopoietic stem cells from their niches by signaling through the β3 adrenergic
receptor26. Nestin+ mesenchymal stem cells express this receptor which regulates the
production of stem cell retention factors27. Because acute MI raises blood progenitor levels
in patients12, we investigated whether SNS activity causes the release of HSPCs from the
bone marrow after MI. Blood HSPCs decreased by 100, 75, and 50% at 6, 48, and 96 hours
after MI in mice treated with a β3 receptor antagonist (Fig. 3a). The stem cell retention
factor CXCL12, angiopoietin and stem cell factor (SCF)28 underwent similar regulation
(Fig. 3c). Levels of the adhesion molecule VCAM-1, which also retains HSPCs in the bone
marrow, decreased after MI but did not change after β3 receptor blocker administration (Fig.
3c). These data indicate that increased sympathetic tone after MI causes withdrawal of stem
cell retention factors by β3 adrenoreceptor-expressing niche cells.
Treatment with a β3 adrenergic blocker reduced splenic accumulation of progenitors in wild
type mice shortly after MI (Supplementary Fig. 18) and consequently diminished their
output of myeloid cells (Supplementary Fig. 19). In apoE−/− mice 3 weeks after MI, β3
blocker treatment reduced the number of GMPs and their progeny in the spleen and blood
(Supplementary Fig. 20). Retrospective analysis of a clinical trial29 revealed that prior β-
blocker therapy was associated with a reduction in monocytes after an acute coronary
syndrome (Supplementary Table 1). The mechanism that led to this decrease is unclear, also
because some clinically used β-blockers have a lower affinity for the β3 receptor subtype30;
however, these associative data show an interesting parallel to our findings in mice.
In apoE−/− mice after MI, β3 blocker treatment lowered protease activity, myeloid cell
content, and mRNA levels of inflammatory cytokines in the plaque (Supplementary Fig. 21).
When we adoptively transferred GFP+ GMPs to wild-type mice with MI, β3 blocker
treatment did not alter their splenic differentiation (Supplementary Fig. 22). Sympathetic
denervation with 6-hydroxydopamine (6-OHDA)26,31 increased bone marrow mRNA levels
of the stem cell retention factor CXCL12, reduced levels of HSPCs in blood, decreased
circulating monocyte levels, and attenuated the accumulation of myeloid cells in
atherosclerotic lesions (Supplementary Fig. 23). Combination of β3 blockade and
splenectomy showed no additive effects (Supplementary Fig. 24). Neither MI nor β3
blockade changed blood cholesterol and HDL levels (Supplementary Fig. 25).
IVM of HSPC departure from bone marrow
We adoptively transferred lineage− c-kit+ Sca-1+ Flk2− HSPCs labeled with a fluorescent
membrane dye (DiD) to examine their release with serial intravital microscopy32. DiD+ cells
were quantified after they had settled into the bone marrow, and then again 4 days after MI.
Concomitant with the post-MI increase of progenitors in circulation, 52% of cells that were
present during the first imaging session departed from the bone marrow, which was
inhibited by the β3 receptor antagonist (Fig. 4). Post-imaging flow cytometry corroborated
the trafficking of DiD+ cells (Supplementary Fig. 26). We next investigated the relocation of
bone marrow cells to the spleen directly. Lineage− c-kit+ Sca-1+ Flk2 − HSPCs were
harvested from CD45.2+ donors and labeled with a photoconvertible dye before transfer into
CD45.1+ recipients. These cells engrafted into the skull bone marrow, where we
photoconverted them with laser illumination. Only if mice underwent coronary ligation,
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tphotoconverted CD45.2+ DAPI+ cells were detected in splenic cell suspensions 4 days later
(Supplementary Fig. 27).
Splenic HSPC engraftment after MI
Finally, we investigated the mechanisms of splenic progenitor seeding. The mRNA levels of
stem cell factor (SCF) increased in splenic tissue after MI in parallel with the number of
SCF+ cells in splenic sections (Fig. 5a,b). Antibody neutralization of SCF decreased
retention and proliferation of adoptively transferred HSPCs in the spleen (Fig. 5c,d).
Colocalisation studies identified CD31+ and occasionally nestin+ cells (Supplementary Fig.
28a,b) as a source of SCF, in agreement with a recent report on SCF's role in the splenic
niche during the steady state33. We found adoptively transferred DiD+ Flk-2− HSPCs cells
in close vicinity to CD31+ cells (Supplementary Fig. 28c). Neutralization of VLA-4, an
integrin involved in stem cell retention34,35, reduced the number of adoptively transferred
HSPCs in the spleen after MI, but not in the steady state (Supplementary Fig. 29).
DISCUSSION
This study reports that acute MI or stroke augments inflammation in atherosclerotic plaques
at a distance. After an ischemic event, atherosclerotic plaque grew faster and displayed
higher protease activity. We identified an increased supply of innate immune cells as a
driving force for this phenomenon. On a systems level, pre-existing chronic inflammation
flared when the organism experienced an additional acute inflammatory stimulus. Increased
sympathetic nervous system activity after MI released upstream progenitors from bone
marrow niches. On the receiving end, the spleen hosted these cells by increasing SCF
production, leading to amplified extramedullary myelopoiesis (Paradigm, Fig. 5e). The pro-
inflammatory changes in atherosclerotic plaques persisted for several months.
The evolutionary benefit of outsourcing myelopoiesis from the bone marrow may involve
the protection of steady state "housekeeping" in this confined compartment. Unlike the bone
marrow, the spleen is an organ that can rapidly expand in size. In the event of increased
leukocyte need after acute injury, the myelopoietic system may proliferate in extramedullary
sites to protect quiescent stem cells and to ensure unimpeded production of red cells,
platelets and lymphocytes in the bone marrow.
Despite growing understanding of the chronic inflammatory nature of atherosclerosis3,6,7,
specific anti-inflammatory therapy has yet to materialize. Given myeloid cells’ central role
in disease promotion and their rapid turn-over in inflamed tissue, interrupting the monocyte
supply chain may attenuate atherosclerosis. In our case, SNS inhibition abrogated stem cell
release from the bone marrow. Since the regulation of progenitor cell migration is
multifactorial35, there are other targets along this pathway that await exploration, including
chemokine receptors and cytokines involved in stem cell activation. In addition, the innate
immune response unleashed by acute ischemic injury may also change the “fluid phase” of
blood by augmenting circulating acute phase reactants such as fibrinogen and plasminogen
activator inhibitor-1, factors that promote thrombosis and counter endogenous fibrinolysis36.
Our study suggests that patients with an ischemic complication of atherosclerosis experience
a particularly vulnerable disease phase, and that interventions aiming at progenitors of innate
immune cells could profoundly impact long-term outcomes.
METHODS SUMMARY
Wild-type C57BL/6J, C57BL/6.SJL, C57BL/6-Tg(UBC-GFP)30Scha/J and B6.129P2-
Apoetm1Unc/J mice were used in these studies, which were approved by the Subcommittee
on Animal Research Care at Massachusetts General Hospital (13th Street, Charlestown,
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tMA). The patient studies were conducted in accordance with the Declaration of Helsinki.
The studies were approved by the Research Committee of the Department of Pathology of
the VUmc, Amsterdam and by the Ethikkommission Heidelberg University (Voss Str. 9,
Heidelberg, Germany). Detailed procedures are available online at www.nature.com/nature.
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Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Increased inflammation in atherosclerotic plaques after MI
a, Protease activity by FMT-CT before and 3 weeks after MI. Circles indicate aortic root (n
= 10 per group). b, Protease activity in excised aortae by fluorescence reflectance imaging
(FRI), expressed as target to background ratio (TBR, n = 10 per group). c, Flow cytometric
quantification of myeloid cells and Ly-6Chigh monocytes in aorta (n = 5–9 per group). Dot
plots 3 weeks after MI are shown. d, CD11b staining and lesion size (n = 9–10 per group).
Scale bar represents 150 μm. Mean ± s.e.m., * P < 0.05, ** P < 0.01.
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tFigure 2. Elevated levels of progenitor cells in the spleen of apoE−/− mice after MI
a, Quantification for HSPCs, MDPs, and GMPs at different time points after MI (n = 3–15
per group). The gating strategy is shown in Supplementary Fig. 10. b, Number of colony-
forming units. Mean ± s.e.m., * P < 0.05, ** P < 0.01.
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tFigure 3. β3 adrenergic receptor-mediated progenitor release after MI
a, Flow cytometric analyses of HSPC in blood of C57BL/6 mice (n = 6–11 per group). b,
Immunostaining for tyrosine hydroxylase (TH). Scale bar represents 10μm. Insets depict
low magnification overview. Bar graph shows quantitation of TH+ area (n = 5 per group). c,
Expression of HSPC retention factors (relative to Gapdh) in the bone marrow of C57BL/6
mice on day 4 after MI (n = 8 per group). Mean ± s.e.m., * P < 0.05, ** P < 0.01.
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tFigure 4. Serial intravital imaging of progenitor release from the bone marrow
a, DiD labelled-HSPC Flk2− cells were imaged in the skull bone marrow by intravital
microscopy (IVM) before and then again 4 days after MI. DiD labelled-HSPC are white,
blood pool red, and bone is blue. The scale bar represents 50 μm. b, Change of HSPC
presence between 1st and 2nd IVM session (n = 3 per group). Mean ± s.e.m., * P < 0.05.
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tFigure 5. Splenic progenitor engraftment after MI
a, qPCR of SCF in spleen (n = 5–6 per group). b, Number of SCF+ cells in spleen of
C57BL/6 mice 4 days after MI by immunofluorescence. c, Enumeration of adoptively
transferred GFP+ HSPCs on day 4 after MI (n = 8 per group). d, Proliferation of endogenous
HSPCs determined by BrdU incorporation (n = 8 per group). e, Paradigm. Mean ± s.e.m., *
P < 0.05, ** P < 0.01.
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